Literature DB >> 8427958

Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells.

G Brunner1, H Nguyen, J Gabrilove, D B Rifkin, E L Wilson.   

Abstract

We have shown previously that basic fibroblast growth factor (bFGF) is a mitogen for human bone marrow (BM) stromal cells and that bFGF stimulates myelopoiesis in primary BM cultures. In this article, we demonstrate the presence of bFGF in two cell lineages in human BM and peripheral blood as well as the deposition of bFGF into the extracellular matrix of BM stromal cell cultures. In immunofluorescence experiments on BM and peripheral blood smears, megakaryocytes and platelets stained strongly for bFGF, whereas weaker staining was observed in immature and mature cells of the granulocyte series. The presence of bFGF in platelets was confirmed by enzyme-linked immunosorbent assay as well as by immunoprecipitation followed by immunoblotting. bFGF was synthesized by BM stromal cell cultures and was found either cell associated or localized in the nucleus and the nucleoli, and its location was dependent on the fixation procedure used. Addition of exogenous bFGF to stromal cells showed the presence of extracellular binding molecules for this cytokine. bFGF could be released from these sites by soluble heparin or phosphatidylinositol-specific phospholipase C. This study supports the role of bFGF as a stromal cell mitogen and stimulator of myelopoiesis. The data indicate that the stromal cells produce bFGF and that their extracellular matrix can serve as a reservoir for this growth factor. In addition, the results suggest a possible involvement of bFGF in platelet function as well as in megakaryocytopoiesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427958

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism.

Authors:  Chad M Novince; Megan N Michalski; Amy J Koh; Benjamin P Sinder; Payam Entezami; Matthew R Eber; Glenda J Pettway; Thomas J Rosol; Thomas J Wronski; Ken M Kozloff; Laurie K McCauley
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

2.  Mechanism and Function of Angiogenin in Hematopoietic Malignancy.

Authors:  Kevin A Goncalves; Guo-Fu Hu
Journal:  Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao       Date:  2015-12-23

3.  Myeloid-specific TGF-β signaling in bone promotes basic-FGF and breast cancer bone metastasis.

Authors:  X Meng; A Vander Ark; P Lee; G Hostetter; N A Bhowmick; L M Matrisian; B O Williams; C K Miranti; X Li
Journal:  Oncogene       Date:  2015-08-17       Impact factor: 9.867

Review 4.  Progress against cancer.

Authors:  S Broder; J E Karp
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Authors:  Elie Traer; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Jacqueline Martinez; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

6.  Cytokine production by a megakaryocytic cell line.

Authors:  B Sandrock; K M Hudson; D E Williams; M A Lieberman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

Review 7.  The role of platelets in tumour growth.

Authors:  K Pilatova; L Zdrazilova-Dubska; G L Klement
Journal:  Klin Onkol       Date:  2012

8.  Platelet neuropeptide Y is critical for ischemic revascularization in mice.

Authors:  Jason U Tilan; Lindsay M Everhart; Ken Abe; Lydia Kuo-Bonde; Dan Chalothorn; Joanna Kitlinska; Mary Susan Burnett; Stephen E Epstein; James E Faber; Zofia Zukowska
Journal:  FASEB J       Date:  2013-03-01       Impact factor: 5.191

9.  Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway.

Authors:  S Kamura; Y Matsumoto; J-I Fukushi; T Fujiwara; K Iida; Y Okada; Y Iwamoto
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

10.  Dual FGF-2 and intergrin alpha5beta1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy.

Authors:  Judith Barrios; Robert Wieder
Journal:  Cancer Microenviron       Date:  2009-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.